News: Medicine

View:

2008

 

Found press releases

 

Change in the number of shares of MEDA AB

12/30/2008 9:00 AM EST  -   MEDA
Pursuant to chapter 4, section 9 of the Financial Instruments Trading Act (1991:980), this notice hereby declares that as of 31 December 2008, the number of shares of Meda is 302,243,055. This is an increase of 43,177,580 shares compared to the previous month. The increase is due to shares newly issued in conjunction with Meda’s 2008 preferential rights issue.

Extraordinary General Meeting of Q-Med AB (publ)

12/29/2008 2:00 AM EST  -   Q-Med
The Board of Directors of Q-Med AB (publ) has published a notice to attend the Extraordinary General Meeting, which will be held on Wednesday February 4, 2009 at 3 p.m. on Q-Med’s premises. Entrance from Fyrisvallsgatan 5, Uppsala, Sweden. A notice has been published in Upsala Nya Tidning, Svenska Dagbladet and in Post- och Inrikes Tidningar (Swedish Official Gazette). The complete notice of the Extraordinary...

LEADING EUROPEAN UNIVERSITIES CHOOSE ELEKTA TO DELIVER ADVANCED 3D BRAIN MAPPING...

12/22/2008 9:00 AM EST  -   Elekta
Elekta Neuromag®, the world-leading equipment for non-invasive measurement of brain activity using magnetoencephalography (MEG) technology has been ordered by the Moscow Municipal University of Psychology and Education (Moscow, Russia) and the University of Trento (Trento, Italy).
MEG is a powerful tool for studying normal brain function and brain disorders. Elekta Neuromag is the world’s most advanced and most...

Getinge’s new share issue over subscribed

12/22/2008 7:02 AM EST  -   Getinge Group
Press release December 22, 2008

Not for release, publication or distribution, directly or indirectly, in the United States, Canada, Australia, Hong Kong or Japan

The preliminary calculation of the outcome of Getinge AB’s (Getinge) rights issue shows that approximately 23 597 056 shares, representing approximately 99 per cent of the total rights issue, have been subscribed for with primary preferential rights....

Lyftet Holding B.V. requests an extra shareholders’ meeting in Q-Med AB

12/18/2008 11:02 AM EST  -   Q-Med
The board of directors in Q-Med AB has received from Lyftet Holding B.V. a request for summoning of an extra shareholders’ meeting for election of a new board of directors, subject to the limitations set out in Q-Med’s articles of association.

As soon as a date for a shareholders’ meeting has been settled, January 2, 2009 at the latest, a press release will be distributed and a notice will be published in Svenska...

Management changes at RaySearch

12/17/2008 5:32 AM EST  -   RaySearch Laboratories
During the autumn, RaySearch has reorganized its Development Department to adapt the structure to the large expansion in the number of employees involved in development in recent years. As part of this reorganization, the previous Product Director Anders Murman has taken over as Director of Development and, consequently, assumed full responsibility for the daily development work. The former Director of Development...

ELEKTA’S HEAD OF REGION ASIA DEAD IN PLANE CRASH

12/15/2008 4:10 AM EST  -   Elekta
Press Release
Stockholm, Sweden, December 15, 2008
Yesterday, Sunday December 14, Elekta received the tragic news that Gerrit (Gerry) van Oortmarssen, head of Business Region Asia and member of the company’s Executive Committee, has died in a plane crash in Austria.

Gerry van Oortmarssen was 65 years old. He was employed in Elekta in 1997. Over the years, he held several leading positions in the Elekta...

MERCK & CO., INC. ENTERS PHASE I CLINICAL DEVELOPMENT WITH KARO BIO COLLABORATIO...

12/15/2008 3:45 AM EST  -   Karo Bio
Karo Bio today announced that an estrogen receptor compound discovered as part of its research collaboration with Merck & Co., Inc. has entered Phase I clinical development.
The collaboration with Merck targets estrogen receptors with the aim to develop novel treatments in the field of women’s health. The joint drug discovery phase of the collaboration with Merck was completed in 2002. This compound is the...

Ivytan announced on the 11 December, 2008 that the offer to Q-Med’s shareholders...

12/12/2008 2:10 AM EST  -   Q-Med
Ivytan, indirectly owned by EQT V and Lyftet Holding B.V., a company controlled by Bengt Ågerup, announced on the 11 December, 2008 that the public offer to acquire all shares in Q-Med at SEK 39 per share in cash is withdrawn as the conditions were not satisfied during the acceptance period that ended on Monday 8 December, 2008. The Independent Board Committee.

ASTRAZENECA RESPONDS TO FDA JOINT ADVISORY COMMITTEES’ RECOMMENDATION ON SYMBICO...

12/12/2008 2:03 AM EST  -   AstraZeneca
On 11 December 2008, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) – including the Drug Safety & Risk Management Advisory Committee, the Pediatric Advisory Committee, and the Pulmonary-Allergy Drugs Advisory Committee – completed a review of the benefits and risks of asthma medications containing long-acting beta-agonists (LABAs). The committees concluded that the benefits of...